Kim Chang-Keun, Park Jin-Sung, Chu Shou-Yu, Kwon EunMi, Kim Hanna, Callaway Zak
Asthma and Allergy Center, Department of Pediatrics, Inje University Sanggye Paik Hospital, Seoul, Korea.
Department of Pediatrics, Kangwon University Hospital, Chuncheon, Korea.
Asia Pac Allergy. 2020 Oct 28;10(4):e43. doi: 10.5415/apallergy.2020.10.e43. eCollection 2020 Oct.
The most important infectious trigger of asthma is the virus and patients with immunoglobulin deficiencies are prone to recurrent respiratory infections.
We investigated the relationship between immunoglobulin G subclass and recurrent respiratory symptom exacerbation and explored possible therapeutic effects of intravenous immunoglobulin administration.
Twenty-eight infants less than 24 months old with 2 or more recurrent wheezing episodes (infantile wheezer group) and 29 asthmatic children aged 24 months to 15 years (bronchial asthma [B-asthma] group) visited our hospital from October 2010 to January 2018. Serum immunoglobulin G, A, M, E, G1, G2, G3, and G4 were measured in each group and compared. In both groups, serum immunoglobulin and symptoms were compared before and after intravenous immunoglobulin administration.
The 2 study groups exhibited several statistically significant differences when comparing respiratory virus infection rate ( < 0.001), coinfection rate ( < 0.0001), most commonly found viral infection (human bocavirus vs. human rhinovirus), and immunoglobulin A ( < 0.001), E ( = 0.008), G2 ( < 0.001), and G4 ( = 0.011) levels. In the infantile wheezer group, there was an inverse correlation between immunoglobulin G4 levels and wheezing numbers ( = -0.5538, = 0.0022). Both groups showed significant changes in immunoglobulin levels and respiratory symptom exacerbations (recurrent wheezing, shortness of breath, chest tightness, cough, and fever) over 1 year after intravenous immunoglobulin administration.
There was an association between recurrent wheezing and specific immunoglobulin G deficiencies. We suggest that intravenous immunoglobulin therapy significantly elevates specific immunoglobulin G levels though it lasts only for short term and might be associated with decreased respiratory symptoms. Therefore, low IgG4 levels among infants with recurrent wheezing may be indicative for intravenous immunoglobulin therapy.
哮喘最重要的感染触发因素是病毒,免疫球蛋白缺乏的患者易反复发生呼吸道感染。
我们研究了免疫球蛋白G亚类与反复呼吸道症状加重之间的关系,并探讨了静脉注射免疫球蛋白的可能治疗效果。
2010年10月至2018年1月期间,28名年龄小于24个月且有2次或更多次反复喘息发作的婴儿(婴儿喘息组)和29名年龄在24个月至15岁的哮喘儿童(支气管哮喘[B-哮喘]组)到我院就诊。测量每组的血清免疫球蛋白G、A、M、E、G1、G2、G3和G4,并进行比较。在两组中,比较静脉注射免疫球蛋白前后的血清免疫球蛋白和症状。
在比较呼吸道病毒感染率(<0.001)、合并感染率(<0.0001)、最常见的病毒感染(人博卡病毒与人鼻病毒)以及免疫球蛋白A(<0.001)、E(=0.008)、G2(<0.001)和G4(=0.011)水平时,两个研究组表现出一些统计学上的显著差异。在婴儿喘息组中,免疫球蛋白G4水平与喘息次数之间存在负相关(=-0.5538,=0.0022)。两组在静脉注射免疫球蛋白1年后,免疫球蛋白水平和呼吸道症状加重(反复喘息、呼吸急促、胸闷、咳嗽和发热)均有显著变化。
反复喘息与特定免疫球蛋白G缺乏之间存在关联。我们认为,静脉注射免疫球蛋白治疗虽仅能短期显著提高特定免疫球蛋白G水平,但可能与呼吸道症状减轻有关。因此,反复喘息婴儿中低IgG4水平可能提示静脉注射免疫球蛋白治疗。